Endologix Appoints Chief Commercial Officer

Endologix Inc., a developer and marketer of treatments for aortic disorders, has appointed John D. Zehren as its chief commercial officer, effective immediately.
 
Zehren brings to Endologix more than 20 years of commercial, sales and marketing, and business development experience in the medical device industry. Most recently, he served as vice president of Sales, Americas, at Medtronic Neurovascular and was a senior member of the company’s Neurovascular Management Board. While at Medtronic, he developed and implemented a strategic commercial plan to double revenue in five years. Prior to that, he spent five years as vice president of Sales at Covidien and ev3. Earlier in his distinguished career, Zehren spent over a decade at Edwards Lifesciences, the last four years of which were in the role of vice president of Sales and Marketing.
 
Endologix CEO John Onopchenko said, “We are proud to welcome John, an accomplished commercial medical device leader, to our executive team. He has demonstrated a strong track record of achievement, consistently implementing successful commercial strategies that resulted in impressive growth, share gains, and customer loyalty. We believe John will play a critical role in strengthening and extending Endologix’s customer partnerships and commercial execution, while leading the company’s global go-to-market strategy for our AFX2, Ovation, and Nellix platforms.”

Zehren earned a bachelor of arts degree in biology from College of St. Thomas in Minnesota.
 
”I’m excited to join an organization that has driven so much innovation in the cardiovascular segment and believe that we have an excellent opportunity to strengthen our customer partnerships and secure increased market share and procedural growth around the globe,” Zehren said. “I look forward to working with the Endologix team to drive commercial excellence and bring our differentiated, life-saving technology to more patients in need.”
 
Endologix Inc. develops and manufactures minimally invasive treatments for aortic disorders. The company’s focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80 percent, making it a leading cause of death in the United States.